Lung inflammatory pathway

The "lung inflammatory pathway" describes a complex network of cellular and molecular mediators that regulate the initiation, propagation, and resolution of inflammation within lung tissues. These pathways integrate signals from cytokines, chemokines, cell-surface receptors (e.g., RAGE, IL receptors), intracellular cascades (NF-κB, JAK/STAT, MAPK, PI3K/AKT), and diverse immune and structural cells (macrophages, T cells, epithelial cells). Dysregulation contributes to acute and chronic pulmonary diseases, including infections, ARDS, COPD, cystic fibrosis, interstitial lung diseases, and tumorigenesis. Because this term encompasses many distinct drug targets and signaling axes, it is not considered a single "therapeutic target" but rather an overarching biological process or group of related targets. In summary, "lung inflammatory pathway" is not a precise or canonical therapeutic target but rather refers to a constellation of signaling mediators; structured database curation should instead catalog specific molecules or receptors (e.g., "Interleukin-6 receptor", "RAGE", "CXCR2") within these pathways for mechanistic or drug-target mapping.

Other names

Lung inflammation pathwayPulmonary inflammatory signalingLung immune response pathwaysInflammatory signaling in lung

Inhibition of cytokine signaling (e.g., anti-IL-6, anti-TNF therapies); Suppression of immune cell infiltration (e.g., corticosteroids); Modulation of specific signaling pathways like JAK/STAT, MAPK, NF-κB, PI3K/AKT, etc.; Blockade of cell surface receptors involved in inflammation (e.g., RAGE, CXCR1/2).